Advanced Parkinson’s Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Advanced Parkinson’s Disease Market Outlook
Thelansis’s “Advanced Parkinson’s
Disease Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2024 To 2034" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Advanced Parkinson’s Disease
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
Advanced
Parkinson’s Disease Overview
Advanced
Parkinson’s Disease is a late-stage progression of this neurodegenerative
disorder, with a multifaceted interplay of motor and non-motor impairment that
severely impairs quality of life and daily activities. With additional loss of
dopaminergic neurons in the substantia nigra, patients have more severe motor
fluctuations, dyskinesias, freezing of gait, postural instability, and risk of
falls, usually making them dependent on caregivers. Non-motor
features—cognitive impairment, hallucinations, autonomic dysfunction, sleep
disturbances, and mood disorders—take over and become refractory to
conventional therapies, making treatment more difficult. Levodopa is still the
mainstay of therapy, but decreasing efficacy and side effects at advanced
stages make it necessary to use adjunctive measures, such as dopamine agonists,
MAO-B inhibitors, and device-based approaches like DBS or levodopa-carbidopa
intestinal gel infusion. Multidisciplinary care in neurology, physical therapy,
psychiatry, and palliative care is needed to meet the changing needs of
patients and caregivers. The course of the disease is very unpredictable, and
goal-oriented individualized treatment is essential to preserve autonomy, avoid
complications, and preserve dignity in the face of progressive impairment.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment